Immunoglobulin G1 Anti-(Human Cd33 (Antigen)) (Human-Mouse Monoclonal Hum195 .Gamma.1-Chain), Disulfide With Human Monoclonal Hum195 .Kappa.-Chain, Dimer
Acute Myeloid Leukemia
Explore 588 assets in Acute Myeloid Leukemia →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Actinium Pharmaceuticals
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03932318CT.gov Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | — | Withdrawn | — | — | — |
NCT03867682CT.gov Venetoclax and Lintuzumab-Ac225 in AML Patients | — | Unknown | — | — | — |
NCT03705858CT.gov Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT03441048CT.gov Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02575963CT.gov Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | — | Completed | — | — | — |
NCT00528333CT.gov A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML | — | Completed | — | — | — |
NCT00283114CT.gov A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT00038051CT.gov Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1 Anti-(Human Cd33 (Antigen)) (Human-Mouse Monoclonal Hum195 .Gamma.1-Chain), Disulfide With Human Monoclonal Hum195 .Kappa.-Chain, Dimer (this asset) | Actinium Pharmaceuticals | P2 | B · 60 |
| Gemtuzumab | M.D. Anderson Cancer Center | P4 | A |
| Amsacrine | University Hospital, Toulouse | P4 | BBB |
| Posaconazole | AstraZeneca | P4 | BBB |
| (+)-Vincristine | Janssen Research & Development, LLC | P3 | BBB |
| Aclacinomycin | Chinese PLA General Hospital | P4 | BB |
| Alvocidib | M.D. Anderson Cancer Center | P2 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
| Therapeutic Allogeneic Lymphocytes | University of Southern California | P2 | BB |
+42 more in the Acute Myeloid Leukemia cohort
Other indications for Immunoglobulin G1 Anti-(Human Cd33 (Antigen)) (Human-Mouse Monoclonal Hum195 .Gamma.1-Chain), Disulfide With Human Monoclonal Hum195 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Leukemia | — | P3 | B · 60 |
| Neutropenia | — | P2 | B · 57 |
| Myelodysplastic Syndrome | — | P2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1 Anti-(Human Cd33 (Antigen)) (Human-Mouse Monoclonal Hum195 .Gamma.1-Chain), Disulfide With Human Monoclonal Hum195 .Kappa.-Chain, Dimer in Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-cd33-antigen-human-mouse-monoclonal-hum195-gamma1-chain-disulfide-with-human-monoclonal-hum195-kappa-chain-dimer-acute-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →